...
首页> 外文期刊>Endocrine. >Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer
【24h】

Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer

机译:甲状腺球蛋白抗体和甲状腺过氧化物酶抗体的共存与甲状腺刺激激素水平升高和甲状腺乳头状癌的肿瘤晚期相关

获取原文
获取原文并翻译 | 示例

摘要

The correlation between thyroglobulin antibodies (TgAb) or thyroid peroxidase antibodies (TPOAb) and papillary thyroid cancer (PTC) remains controversial. This histological study aimed to explore the correlation between thyroid autoantibodies (TAb), thyroid-stimulating hormone (TSH), and PTC in patients with thyroid nodules (TN). This was a retrospective study. 2,132 non-autoimmune thyroid diseases (AITD) patients who underwent thyroidectomy were subdivided into: TgAb or TPOAb single positive (TgAb+ or TPOAb+) TN group; TgAb and TPOAb double positive or negative (TAb+ or TAb-) TN group. PTC patients showed a higher rate of TAb-f- TN (10.24 vs. 4.89 %; P = 0.000) and a higher TSH level (1.83 +- 0.07 vs. 1.39 +- 0.03 mlU/L; P = 0.000) than patients with benign nodules. TAb+ TN patients showed a higher TSH level and PTC frequency than those with TAb- TN (1.91 +- 0.17 vs. 1.47 +- 0.03 mlU/L; P = 0.011) (41.35 vs. 22.08%; P = 0.000). In PTC, TAb+ TN patients showed a higher TSH level (2.57 +- 0.35 vs. 1.79 +- 0.07 mlU/L; P = 0.032), a greater frequency of lymph node metastasis (52.73 vs. 36.51 %, P = 0.026), and a lower micro-PTC frequency (16.36 vs. 39.51 %; P = 0.001) than TAb- TN patients. PTC was correlated with TgAb+ TN (OR = 1.921, CI 1.431-2.580; P = 0.000), TPOAb+ TN (OR = 1.945, CI 1.195-3.165; P = 0.007), TAb+ TN (OR = 2.393, CI 1.635-3.501; P = 0.000), and serum TSH >1.35 mlU/L (OR = 1.742, CI 1.089-2.786; P = 0.021). Serum positive TgAb or TPOAb is an independent predictor for PTC regardless of AITD. The coexistence of TgAb and TPOAb confers a greater risk for PTC than isolated positive TgAb or TPOAb, and is correlated with elevated TSH level and advanced PTC stage.
机译:甲状腺球蛋白抗体(TgAb)或甲状腺过氧化物酶抗体(TPOAb)与甲状腺乳头状癌(PTC)之间的相关性仍存在争议。这项组织学研究旨在探讨甲状腺结节(TN)患者的甲状腺自身抗体(TAb),促甲状腺激素(TSH)和PTC之间的相关性。这是一项回顾性研究。将2132例行甲状腺切除术的非自身免疫性甲状腺疾病(AITD)患者细分为:TgAb或TPOAb单阳性(TgAb +或TPOAb +)TN组; TgAb和TPOAb双重阳性或阴性(TAb +或TAb-)TN组。 PTC患者的TAb-f-TN发生率(10.24比4.89%; P = 0.000)和TSH水平更高(1.83 +-0.07比1.39 +-0.03 mlU / L; P = 0.000)良性结节。 TAb + TN患者的TSH水平和PTC频率高于TAb-TN(1.91 +-0.17 vs. 1.47 +-0.03 mlU / L; P = 0.011)(41.35 vs. 22.08%; P = 0.000)。在PTC中,TAb + TN患者的TSH水平较高(2.57 +-0.35 vs. 1.79 +-0.07 mlU / L; P = 0.032),淋巴结转移的频率较高(52.73 vs. 36.51%,P = 0.026),且微型PTC频率低于TAb-TN患者(16.36比39.51%; P = 0.001)。 PTC与TgAb + TN(OR = 1.921,CI 1.431-2.580; P = 0.000),TPOAb + TN(OR = 1.945,CI 1.195-3.165; P = 0.007),TAb + TN(OR = 2.393,CI 1.635-3.501; P = 0.000),血清TSH> 1.35 mlU / L(OR = 1.742,CI 1.089-2.786; P = 0.021)。不管AITD如何,血清阳性TgAb或TPOAb都是PTC的独立预测因子。与孤立的阳性TgAb或TPOAb相比,TgAb和TPOAb的共存赋予PTC更大的风险,并且与TSH水平升高和PTC晚期有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号